Barclays’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
Barclays's PTCT Position: Q3 2026 in Review
Barclays reduced its PTC Therapeutics (PTCT) stake by 18% in Q3 2026, selling an estimated $766K and leaving 47,854 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.
Barclays first reported a position in PTCT in Q3 2013 and has held it in 53 quarters since. The position peaked at $16.7M in Q4 2025. 361 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.
- Barclays held 47,854 shares of PTC Therapeutics worth $3.1M as of Q3 2026.
- Barclays sold 10,516 PTC Therapeutics shares in Q3 2026, an estimated $766K.
- PTC Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2316 holding.
- Barclays first reported a position in PTC Therapeutics in Q3 2013 and has held it in 53 quarters since.
- Barclays's PTC Therapeutics position peaked at $16.7M in Q4 2025.
- 361 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.